Table S1. Investigations in the main clinical study at each time point

Investigation	Inclusion	M6	M12
Informed consent	x		
Inclusion and exclusion criteria	x		
Clinical examination	x	x	x
Therapeutic adherence		x	x
Blood tests (total cholesterol, LDL-c, HDL-c, triglycerides, NT-pro-BNP, troponin high-sensitive)	x		
Electrocardiogram	x	x	x
Echocardiography	x	x	x
Micro-RNAs	x	x	x
Inflammatory markers	x	x	x
X-ray coronary angiography	x	x[a]	x[a]
Optical coherence tomography	x	x[a]	x[a]
Fractional flow reserve	x	x[a]	x[a]
Percutaneous coronary intervention	x[a]	x[a]	x[a]

Coronary computed tomography angiography		x	x
End-points		x	x

Abbreviations: HDL-c, high density lipoproteins-cholesterol; LDL-c, low density lipoproteins-cholesterol; NT-pro-BNP, N-terminal pro brain natriuretic peptide; [a] If deemed necessary according to each particular clinical case.

Table S2. The 79 genes panel for the analysis of the genetic background of subjects included into the study

Gene	Reference
PCSK 9	[1]
IL6R	[2]
SORT1	[2]
PTGS2	[3]
SELE	[4]
VCAM1	[2]
TNNT2	[5]
TRIM63	[6]
ACTN2	[7]
NEXN	[8]
PDGFD	[9]
CYP2C19	[10]
CXCL12	[9]
CYP17A1	[11]
CNNM2	[11]

NT5C2	[11]
ZNF259	[11]
APOA5	[11]
APOA1	[12]
MRVII	[9]
CTR9	[9]
TCF21	[9]
DES	[5]
LRP1	[9]
SCARB1	[9]
SH2B3	[13]
COL4A2	[13]
MYH7	[14]
MYH6	[5]
ACTC1	[5]
ANKS1A	[9]
ADAMTS7	[2]
FURIN	[2]
FES	[11]
CETP	[9]
PECAM1	[15]
ACE	[16]
SMG6	[13]
TCAP	[17]

ITGB3	[18]
PMAIP1	[2]
MC4R	[2]
LDLR	[1]
APOE	[19]
APOC1	[9]
GPI	[14]
TBXA2R	[20]
HDAC9	[9]
TNNI3	[21]
REST-NOA1	[9]
ABCG5	[1]
ABCG8	[1]
WDR12	[2]
APOB	[1]
KCNJ13	[9]
GIGYH2	[9]
P2RY12	[22]
MRAS	[2]
MYL3	[21]
MYOZ2	[23]
EDNRA	[2]
GUCY1A3	[2]
SLC22A4	[2]

SLC22A5	[2]
PHACTR1	[2]
PLA2G7	[24]
PLN	[25]
C2	[9]
LPA	[26]
NOS3	[2]
PON1	[10]
ABCB1	[10]
ZC3HC1	[2]
TRIB1	[13]
LPL	[2]
ABO	[2]
PTGS1	[3]
CDKN2B-AS1	[19]

References

1. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell 2012; 148: 1242–1257.

2. McPherson R, Tybjaerg-Hansen A. Genetics of Coronary Artery Disease. Circ. Res. 2016; 118: 564–578.

3. Lee CR, North KE, Bray MS, et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin. Pharmacol. Ther. 2008; 83: 52–60.

4. Dong ZQ, Wu XJ, Lu QH. Correlations of SELE genetic polymorphisms with risk of

coronary heart disease and myocardial infarction: a meta-analysis. Mol. Biol. Rep. 2014; 41: 3021–3031.

5. Alimadadi A, Aryal S, Manandhar I, Joe B, et al.Identification of Upstream Transcriptional Regulators of Ischemic Cardiomyopathy Using Cardiac RNA-Seq Meta-Analysis. Int. J. Mol. Sci. 2020; 21: 3472.

6. Parry TL, Willis MS. Cardiac ubiquitin ligases: Their role in cardiac metabolism, autophagy, cardioprotection and therapeutic potential. Biochim. Biophys. Acta - Mol. Basis Dis. 2016; 1862: 2259–2269.

7. Arvanitis M, Zhang Y, Wang W, Auton A, et al. Genome-wide association and multi-omic analyses reveal new mechanisms for Heart Failure. Nat. Commun. 2020; 11: 1122.

8. Wu C, Yan H, Sun J, Yang F, et al. NEXN is a novel susceptibility gene for coronary artery disease in Han Chinese. PLoS One. 2013: 8: e82135.

9. Webb TR, Erdmann J, Stirrups KE, et al. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. J. Am. Coll. Cardiol. 2017; 69: 823–836.

10. Ma L, Yuan Y, Li J, et al. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. Int. J. Immunogenet. 2020; 47: 539–545.

11. Cheema AN, Rosenthal SL, Ilyas Kamboh M. Proficiency of data interpretation: identification of signaling SNPs/specific loci for coronary artery disease. Database. 2017; 2017: bax078.

12. Haase CL, Frikke-Schmidt R, Nordestgaard BG, et al. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J. Intern. Med. 2011; 270: 136–146.

13. Elosua R, Sayols-Baixeras S. The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. Rev. Española Cardiol. 2017: 70: 754–762.

14. Lu H, Chen Y, Li L. Metabolic Pathway Genes Associated with Susceptibility Genes to Coronary Artery Disease. Int. J. Genomics. 2018; 2018: 9025841.

15. Listì F, Caruso C, Balistreri CR, Grimaldi MP, et al. PECAM-1/CD31 in infarction and longevity. Ann. N. Y. Acad. Sci. 2007; 1100: 132–139.

16. Žaliaduonytė-Pekšienė D, Lesauskaitė V, Liutkevičienė R, et al. Association of the genetic and traditional risk factors of ischaemic heart disease with STEMI and NSTEMI development. J. Renin. Angiotensin. Aldosterone. Syst. 2017; 18: 1470320317739987.

17. Ibrahim M, Siedlecka U, Buyandelger B, et al. A critical role for Telethonin in regulating t-tubule structure and function in the mammalian heart. Hum. Mol. Genet.; 2013; 22: 372–383.

18. Sheikhvatan M, Boroumand MA, Behmanesh M, et al. Integrin Beta-3 Gene Polymorphism and Risk for Myocardial Infarction in Premature Coronary Disease. Iran. J. Biotechnol. 2019; 17: e1921.

19. Tiret F, Cambien L. Genetics of Cardiovascular Diseases From Single Mutations to the Whole Genome. Circulation 2007; 116: 1714–1724.

20. Peng LL, Zhao YQ, Zhou ZY, et al. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol. Sin. 2016; 37: 1442–1448.

21. Jiang DS, Zeng HL, Li R, et al. Aberrant Epicardial Adipose Tissue Extracellular Matrix Remodeling in Patients with Severe Ischemic Cardiomyopathy: Insight from Comparative Quantitative Proteomics. Sci. Rep. 2017; 7: 43787.

22. Li M, Wang H, Xuan L, et al. Associations between P2RY12 gene polymorphisms and

risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine (Baltimore) 2017; 96: e6553.

23.   Gladka MM, Molenaar B, de Ruiter H, et al. Single-Cell Sequencing of the Healthy and Diseased Heart Reveals Cytoskeleton-Associated Protein 4 as a New Modulator of Fibroblasts Activation. Circulation 2018; 138: 166–180.

24.   Casas JP, Ninio E, Panayiotou A, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010; 121: 2284–2293.

25.   Davis J, Chouman A, Creech J, et al. In vitro model of ischemic heart failure using human induced pluripotent stem cell–derived cardiomyocytes. JCI Insight 2021; 6: e134368.

26.   Burgess S, Ference BA, Staley JR, et al. European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018; 3: 619–627.